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ABSTRACT
SAWYER DULANEY AND BAILEY TAYLOR: Covalent Modification of Recombinant
Protein with Reactive Thiols (Under the direction of Dr. Susan Pedigo)

Many diseases cause chronic and painful inflammation in different body systems. One of
the front-line drug classes to treat such inflammation is Nonsteroidal Anti-Inflammatory Drugs
(NSAIDs). Despite the benefits of oral administration of NSAIDs, there are drawbacks to their
long-term usage because they can cause detrimental effects on off-target systems in the body such
as the liver, kidney, or the lining of the intestinal tract. An alternative to NSAIDs is the usage of
hydrogels for targeted drug delivery. Hydrogels can provide drug delivery in a specific portion of
the site of inflammation, thus allowing higher doses of medication to be able to be given without
the risks of damage to other body systems. Our lab has developed a Calmodulin: M13 peptidebased hydrogel system for this purpose which is the focus of this study.
The purpose of these experiments was to develop a method to modify CCLP3, the
calmodulin component of our hydrogel, to create more sulfhydryl groups such that there are more
attachment sites for future modification by a drug. There are three methods of modification
explored in this study: the reaction of CCLP3 with Traut’s Reagent (2-iminothiolane) in an aerobic
environment; the reaction of CCLP3 with Traut’s Reagent in an anaerobic environment; and, the
reaction of CCLP3 with SATA (N-succinimidyl S-acetylthioacetate ) in an anaerobic environment.
Traut’s Reagent and SATA have unique chemistries, each with its potential upsides and
downsides. This work reports the results of the modification of CCLP3 with these reagents and the
subsequent analysis of the products using Ellman’s reagent.
The quantification of sulfhydryl group addition with Ellman’s Reagent concluded that each
method resulted in differing levels of modification to CCLP3. There are twenty-six potential sites
iv

of modification on CCLP3, and the reagents provided total potential modification percentages of
11.7% for Traut’s Reagent in an aerobic environment, 37.4% for Traut’s Reagent in an anaerobic
environment, and 19.1% for SATA in an anaerobic environment. After consulting the literature,
we have determined two potential areas of improvement by increasing the molar ratio of reagent
to CCLP3. In future experiments, we recommend adding a non-sulfur-containing reducing agent
such as TCEP to prevent disulfide linkages while still allowing quantification of sulfhydryl groups
using Ellman’s Reagent.

v

TABLE OF CONTENTS
LIST OF TABLES

vii

LIST OF ABBREVIATIONS

ix

CHAPTER 1: INTRODUCTION

1

CHAPTER 2: CHEMISTRY

13

CHAPTER 3: MATERIALS AND
METHODS

21

CHAPTER 4: RESULTS

30

CHAPTER 5: DISCUSSION

39

LIST OF REFERENCES

45

vi

LIST OF TABLES AND FIGURES
FIGURE 1.1

A Potential Reaction Map for CCLP3

3

FIGURE 1.2

Calmodulin’s Structure and Properties

8

FIGURE 1.3

Schematic of Polymers in Co-polymeric Hydrogel

10

FIGURE 1.4

CaM Binds with Peptide

11

FIGURE 1.5

Formation of Hydrogel

12

TABLE 2.1

Relevant Characteristics of CCLP3 and PCLP3

14

FIGURE 2.1

Reactivity of Traut’s Reagent

16

FIGURE 2.2

Lysine and SATA Reaction

18

FIGURE 2.3

SATA-modified Lysine Reaction with Hydroxylamine

19

FIGURE 2.4

The Reaction of Ellman’s Reagent and Cysteine

20

TABLE 3.1

The Ellman’s Reagent Standards

24

FIGURE 3.1

Photo Dialysis under Argon

27

FIGURE 4.1

The Absorbance vs Wavelength of Lyophilized CCLP3

30

FIGURE 4.2

Reducing SDS-PAGE Gel Used to Verify Presence of CCLP3

31

FIGURE 4.3

Reducing SDS-PAGE Used to Check for Presence of CCLP3 after
Dialysis

32

FIGURE 4.4

The Concentration (mM) vs Absorbance of a Cysteine Calibration
Curve and our Purified CCLP3 Sample after Reaction with Traut’s
Reagent

33

FIGURE 4.5

The Concentration (mM) vs Absorbance of a Cysteine Calibration
Curve and our Purified CCLP3 Sample after reaction with Traut’s
Reagent

35

FIGURE 4.6

The Concentration (mM) vs Absorbance of a Cysteine Calibration
Curve and our Purified CCLP3 Sample after reaction with Traut’s
Reagent under Argon

36

vii

FIGURE 4.7

The Concentration (mM) vs Absorbance of a Cysteine Calibration
Curve and our Purified CCLP3 Sample after reaction with SATA
under Argon

37

FIGURE 5.1

Strategy For the Modification of Thiols

44

viii

LIST OF ABBREVIATIONS

CaM

Calmodulin

MLCK

Muscle Light Chain Kinase

MMP

Matrix Metalloproteinases

HCl

Hydrochloric Acid

NaCl

Sodium Chloride

EDTA

Ethylenediaminetetraacetic Acid

SATA

N-succinimidyl S-acetylthioacetate

DMSO

Dimethyl Sulfoxide

HEPES

2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid

Cys

Cysteine

SDS-PAGE

Sodium Dodecyl Sulfate–Polyacrylamide Gel Electrophoresis

Traut’s Reagent

2-iminothiolane

Abs

Absorbance

MW

Molecular Weight

kD

Kilodaltons

D

Daltons

g

Grams

mg

Milligrams

cm

Centimeters

nm

Nanometers

mol

Moles

M

Molar

mM

Millimolar

M

Micromolar

mL

Milliliter

L

Microliter

ix

Chapter 1
Introduction
I.

Introduction
a. Background Information
Chronic and acute inflammation plague patients of all ages with devitalizing diseases. Oral

Nonsteroidal Anti-inflammatory Drugs (NSAIDs) are the first-line treatment to reduce the
symptoms of inflammation, despite the adverse effects that these oral medications can cause1. One
of the largest potential issues with the oral route as a source of anti-inflammatory drug delivery is
the vulnerability of the gastrointestinal tract and the organs that clear the drugs from the body,
namely the liver and kidney2. NSAIDs also endanger the patient’s cardiovascular functions leading
to more prescribed medications3. Thus, paradoxically, oral NSAIDs cause systemic consequences
that produce negative results by disrupting body systems that originally presented no issues.
Therefore, it is important to find an alternative way to dispense NSAIDs that do not produce the
pleiotropic effects that oral administration of medication presents.
Much effort in recent years has been devoted to targeted drug delivery systems or in other
words, in situ drug delivery at specified sites in the body. Hydrogels have emerged as a major
candidate to provide an alternative route to deliver NSAIDs specifically without the negative
impacts presented with oral delivery. Hydrogels are inert materials that can be injected into
inflamed tissues and then serve as an in-situ drug delivery depot. To create such a material,
considerable molecular engineering is required including the design of the hydrogel matrix, which
is a means to carry the drug in the matrix and a signal to release the drug in response to
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inflammation. Work in this area is important because there are a considerable number of people
that would benefit from the finding of an alternative route of medication delivery through
hydrogels due to their unique properties and degradation activity.
Our lab has developed a promising copolymeric, protein-based hydrogel system intended
to dispense NSAIDs in specific extracellular sites where inflammation is a problem. This
copolymer comprises two polymers, one containing Calmodulin (CaM) and the other a peptide
called M13. Since these proteins are from humans, they are unlikely to cause immune responses
in vivo. M13 is a key peptide with 26 amino acids from striated skeletal muscle myosin light chain
kinase (MLCK) that comprises a CaM binding site that is essential for calcium signal transduction
pathways4, 5. M13 and CaM bind each other with high affinity in the presence of calcium, which
is the basis of the noncovalent interactions between our copolymeric hydrogel. This hydrogel is
then to serve as a scaffold for in situ drug delivery.

b. Our Experiment
The long-term goal of this experiment is to establish the chemistry for the use of the CaM:
M13 hydrogel for in situ delivery of NSAIDs at the site of inflammation. The hydrogel would be
a drug depot injected at the specific site of the inflammation such as at the sciatic nerve bundle of
the knee joint. To attach NSAIDs to the hydrogel matrix, we will introduce thiol sites to the CaMbased copolymer, and then subsequently link NSAIDs to those thiols with hydrolyzable linkages.
Once formed into a hydrogel, this would fulfill our goal of creating a copolymeric hydrogel for in
situ drug delivery at specific sites of inflammation in the body.
Details of this proposed process are below (Figure 1.1). The main purpose of the
experiment outlined therein is to create a covalently modified gel matrix for in situ drug delivery.
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The first necessary step in the process (Figure 1.1 (a)) was to develop a process that was suitable
for adding sulfhydryl groups to our CCLP3 protein as NSAID attachment sites. As CCLP3 only
contains one cysteine, we were tasked with adding more sulfhydryl groups onto the protein for
potential reaction sites. Sulfhydryl groups are important to our research as they ultimately provide
the reactive group for the chemical linkage to naproxen, our NSAID of choice. Naproxen is
activated in a separate set of experiments to make material 6 (Figure 1.1) and added to the thiolated
mixture of already formed, and thiol-rich hydrogel in reaction (e). There is a lot of flexibility with
sulfhydryl groups in that they can be easily oxidized or reduced, providing stability to the protein
when needed yet still allowing the ability to be reduced for further reactions if needed.

Figure 1.1: A potential reaction map of CCLP3 to a hydrogel containing naproxen
This scheme shows the activation of the CaM component of the hydrogel (CCLP3) with
Traut’s reagent6 first (a), then it is treated with a bifunctional PEG spacer to create a 3D
gel network (product 3). Mixing it with the M13 peptide component, PCLP3, in the
presence of Ca2+ will promote hydrogel formation. Then the mixing of the prepared
Naproxen (product 6) with activated hydrogel (product 5) will create a naproxen-modified
hydrogel.
In the following sections, we will first address the breadth of uses of injectable hydrogels
for a variety of purposes. Second, we will undertake a comprehensive review of the design
elements of our copolymeric system.
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II.

Hydrogels
The purpose of this section is to provide a brief introduction to hydrogels. Hydrogels, a gel

biomaterial with a hydrophilic nature, are 3D networks of hydrophilic polymers that are wetted by
water and hold water in their stable structures. These hydrated networks of noncovalent
interactions and covalent bonds prevent the collapse of the structure of hydrogels. They can be
made of synthetic or natural polymeric components and mixtures of the two7, 8. Hydrogels may or
may not be deformable, recover from injury, and degrade upon chemical or physiological signals.
They can be used as scaffolds for tissue engineering, or depots for drug delivery as we are
interested in developing. These ideas are discussed below.

A. Hydrogel structure
At the highest level of structure, hydrogels are classified by their interactions and linkages.
Macromolecular hydrogels are defined by their ability to create covalent cross-linkages between
polymeric components. Supramolecular hydrogels are formed through non-covalent interactions
between polymeric components. They tend to have different characteristics that suit them to their
applications. For instance, macromolecular hydrogels tend to not be as good at self-healing after
injury, but they are stronger and purposed for bearing weight. Crosslinked hydrogels are insoluble;
supramolecular hydrogels will erode. Thus, if the hydrogel should degrade as part of its function
in vivo, then a supramolecular hydrogel would be a better choice. Both forms of hydrogels have
characteristics that contribute significantly to their functional attributes9, 10.
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B. Hydrogel Applications
Hydrogels have been applied in tissue engineering, wound dressing, and contact lenses8.
These applications are very specific site-specific needs that each require tailored properties such
as beyond biocompatibility, such as mechanical strength, pain relief, antiseptic delivery, and
corrective properties for the contact lenses. Hydrogels can also be used for in situ drug delivery
through transdermal patches, surgical implantation, and systemic delivery via intravenous
infusion11. The latter of these two methods is problematic due to patient discomfort involved in
surgery and potential hazard in intravenous injection. For that reason, there is great interest in
injectable hydrogels that can stabilize and serve as a stable drug delivery depot in the extracellular
matrix at the site of inflammation in vivo12. In terms of chronic inflammatory diseases that require
a long duration of treatment and slow NSAID release, tunable, injectable hydrogels are the perfect
solution. Previous applications of many drug delivery hydrogels have been limited for the usage
of drug delivery because of their delicate properties and weak mechanical strength10. Two
examples of how crosslinking agents can control injectable hydrogels are noted here. Brindha, et
al (2019) explored the use of cross-linking agents as a means of transitioning supramolecular to
macromolecular hydrogels to allow control over the viscoelasticity of the resultant gel13. The
physical characteristics of protein-based hydrogels made from elastin are temperature dependent,
including degradation by proteases, dependable composition, and viscoelasticity, and can be
altered to adjust accordingly in a specific chemical component14.
To create a responsive hydrogel, it is commonly desirable to design the hydrogel-specific
elements according to the purpose. The characteristics of their interactions and bonds can permit
a drug’s release at sites of inflammation only when required by the body through signaling and
activation of chemical processes (c.f. Devapally, et al15). The filamentous structure’s chemical
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cross-linking must be maintained for efficient usage in their purpose of drug delivery along with
their biodegradable mechanism until they have slowly expended all their internal and useful
components16. An influx in physiological calcium levels in extracellular space and the crosslinking
of hydrogels help regulate the rate of expending all their materials which is attributable to calcium
signaling that allows self-assembly of drug delivery.
Within the last century, research has been conducted by Senapati, et al (2018) to explore
hydrogel’s applications to chemotherapeutic solutions to solid, cancerous tumors. Often,
chemotherapy, like NSAIDs, negatively harms other bodily regions free of cancer, but due to
hydrogel’s biocompatibility, they provide an alternative means to encapsulate and target-apply a
hydrogel composed of biomacromolecules. The physiological pH and temperature, at which
hydrogels perform a slow release of drug, can be altered to release faster at a more acidic pH
attributable to its cross-linkages; however, hydrogels also characterize themselves due to minute
cytotoxicity making hydrogels a ‘promising candidate for the controlled delivery of
chemotherapeutics’ and a plausible solution to the negative side effects that currently conventional
anti-cancer drugs have on interconnected body systems17.
Hydrogels are highly applicable to a wide variety of physiological inflammatory situations.
Atherosclerosis, which is a disease characterized by aberrant arterial fat deposition, is an
inflammatory disease in arteries that are localized to a very specific compartment and
inflammatory pathway. Yi, et al (2020) have designed a synthetic polymer that can be injected into
the inflamed area to deliver a form of vitamin D to disrupt the aberrant immune response in the
arteries associated with dendritic cells. The polymer works as a crosslinked network that entraps
the vitamin D. In the extracellular space around the heart, the hydrogel network is oxidized into a
micellar structure to allow for the dispersion of medication to be physiologically regulated by
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changes in the oxidation levels. These hydrogels can then respond to changing oxidation levels
through chemical transformation to provide a transport mechanism for the medication in vivo for
weeks or months16.
Through another application of hydrogels, we can recognize their importance in tissue
reformation. Damaged tissue and skin wounds can vary by their degree of severity and ability to
regenerate themselves because it involves regulating the inflammatory response to restore the
properties of the extracellular matrix composed of proteins like collagen, polysaccharides, and
glycosaminoglycans18. The extracellular matrix in this situation is responsible for cell
proliferation, signaling, and repairs to the physiological system that are assisted by the presence of
collagen, a component in the dermis and extracellular matrix connective tissue, but for a wound
lacking collagen, many collagen-based skin restoration products are strenuous to apply and
maintain care leading to irregular formations of skin. When collagen-based hydrogels are applied,
their water-bearing properties along with restorative collagen create a fluidity filling the conformal
layers of wounds that create a more normal-looking skin topography18. This allows for not only an
appeasing physical appearance but also restoration of the nature of damaged epidermal tissue.
They implemented a hydrogel drug vehicle that allowed it to adhere and promote endothelial cell
proliferation that will produce and maintain the extracellular matrix.

III.

Calmodulin Hydrogel
A. Overview
As we mentioned before, CaM and M13 provided ideal properties to engineer our hydrogel

since they are naturally found in the body, high binding affinity in calcium4, 5, thus reducing their
immunogenicity and promoting gel formation in vivo. CaM provides extremely stable thermal
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capabilities with a melting point of 115 °C in the presence of calcium, so it can boil to purify and
bind without losing properties. CaM has two EF-hand helix calcium-binding sites in each of two
domains for a total of 4 sites (Figure 1.1). When calcium binds, hydrophobic pockets in the N- and
C-terminal domains become solvent accessible and then interact with target peptides. Hence, the
CaM -M13 peptide interacts in this double mitten wrap action of the two domains of CaM around
the peptide. The peptide is unstructured until CaM binds to it. M13 structure then becomes helical
while CaM’s structure is more compact as it wraps around the peptide as shown in Figure 1.2
below.

Figure 1.2: Ribbon and cartoon drawings calmodulin
Ribbon drawing of 3cln.pdb19 with calcium-binding sites shown in yellow20. Helices lead
into and out of each site. The “central helix” separates two independently folded domains.
When calcium binds, the hydrophobic surface area is exposed at the base of each pair of
sites (orange crescents in the cartoon). These hydrophobic surfaces interact with various
calmodulin-binding agents such as trifluoperazine21 and peptides from physiological
partners (e.g. myosin light chain kinase22 and ryanodine receptor23). In the ribbon24 and
cartoon drawings, the helical peptide from a physiological partner is represented as a green
cylinder.
8

CaM-M13’s self-assembling properties are spontaneous in the extracellular space due to
free calcium ion levels varying between physiological concentrations of 1.1 mM to 1.5 mM25-27.
These are approximately 100 to 1000 times higher than the binding affinities for the N- and Cterminal domains of CaM for calcium4. Thus, the linkage between CaM and M13 will develop in
the presence of calcium ions that is predominantly in the extracellular (EC) space within a body
system. The copolymer’s ability to solubilize after lyophilization and to self-assemble allows for
the optimization of genetically engineered components of the hydrogel. This section will cover the
mechanisms of the synthetically modified proteins used in our experiments.

B. Engineered CaM and M13 Polymers
Two polymers, Calmodulin Collagen-Like Protein (CCLP) and Peptide Collagen-Like
Protein (PCLP) were modified for the intent of this study and are represented by the schematic in
Figure 1.3 below. CCLP3 has three repeating units of CaM while PCLP3 is named by three
repeating segments of M13. They both have a general base of His6 sequences at the N-terminals
that allow for His Tag purification, regions of collagen-seeming sequences between their different
repeated segments that can be cleaved by physiologically occurring matrix metalloproteinases
(MMPs), and C-terminal cysteine residues between each of the polymers used in covalent
modifications.
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CCLP3

PCLP3

Figure 1.3: Schematic of Polymers in Copolymeric Hydrogel
His Tag at the N-terminus (blue line) and calmodulin composed of 148 amino acids
(orange) are followed by a collagen-like sequence with a consensus cleavage site
represented by the green circle, which all compose the CCLP3. At the C-terminus of the
protomer is a Cysteine that provides a thiol group that is modified in the specific
chemistries explored in these studies. The PCLP3 protomer has the M13 peptide
sequence (yellow) instead of Calmodulin and is composed of 26 amino acids at each M13
peptide.

IV.

CCLP3, PCLP3, and Polymers
Physiologically, intracellular calcium levels range from 0.1 to 10 micromolar in the cytosol

of muscle cells where CaM and M13 would normally associate. PCLP3 and CCLP3 in our
hydrogel, which contains the sequences of M13 and CaM, vary extracellular calcium concentration
between ~1 mM, as discussed above. This excess level of calcium will stabilize protein-protein
interactions within the hydrogel. Intracellular CaM binds calcium ions at a high affinity because
calcium concentrations are naturally low in the intracellular matrix, so calcium binds to both Nterminal and C-terminal sites of CaM to open the structure for binding of the target sequence.
When it binds to CaM, CaM undergoes a conformational change that exposes hydrophobic areas
at the base of binding sites, as seen in Figure 1.4 below. M13 from the skeletal muscle myosin
light chain kinase is an appropriate choice of binding partner to CaM because of their high binding
affinity and specific association. It was mentioned before that the bound complex makes M13 more
10

helical and CaM condensed, while the helix connecting the N- and C- terminal domains is
unstructured and can adapt its shape to allow the hydrophobic pockets in the underside of the
binding sites in each domain to interact specifically with the M13 peptide22.

Figure 1.4: CaM binds with Peptide
The N and C terminal sites of the CaM-calcium complex are organized, and the
hydrophobic pocket is exposed allowing for the binding of calmodulin to the intracellular
protein’s target sequences in vivo. Binding created the helical structure of the bound
component.

With similar crosslinking as their basic protein components, CCLP3 and PCLP3 create
noncovalent gel matrices, shown in Figure 1.5 below. Based on previous research in this lab, our
hydrogel is characterized by a few integral aspects. One aspect is that calcium ions are necessary
to promote interactions for forming the supramolecular copolymeric hydrogels to form. Secondly,
when used in vivo to deliver NSAIDs at the site of inflammation, we expect that the more acidic
pH will increase the rate of hydrogel degradation due to the acid-activation of endogenous
proteases28. Third, hydrogel formed from PLCP3 and CCLP3 showed only minor evidence of
reshaping itself once it was deformed, reinforcing the importance of having the structure in the
desired shape be applied. Lastly, the hydrogel did not swell “beyond the total volume of the mixed
components,” which emphasizes the boundaries to how much drug can be utilized in a single
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hydrogel29. The formation of this study’s copolymeric hydrogel, shown in Figure 1.5 below, occurs
due to all of the characteristics aforementioned.

Figure 1.5: Formation of Hydrogel
Left: CaM-based polymer (CCLP3; n=3; blue) and M13-based polymer (PCLP3; n=3;
green) are mixed in the presence of calcium. A complex physical co-polymeric
“supramolecular” hydrogel form (right).

The next section of this review will cover details of the major materials and reactions used
in this work. These include the protein that we studied and the chemistry behind our reactions of
CCLP3 with Traut’s Reagent and SATA for modifying the protein with additional -SH groups.
Finally, we will descript the reaction of the -SH groups with Ellman’s Reagent to determine the
success of the modification of the protein.
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Chapter 2
Chemistry

To acquire a better understanding of the reactions that take place throughout our
experiment, this chapter will explain the chemistry behind those reactions. This chapter will have
a specific focus on CCLP3 and the reactions involving Ellman’s Reagent, Traut’s Reagent, and
SATA.

I.

Characterization of CCLP3 and PCLP3
It is important to introduce the two components that comprise the hydrogel: CCLP3 and

PCLP3. These are recombinant proteins designed in our laboratory by Drs. Fox and Pedigo after
several iterations. The exact sequence of the Collagen-Like Sequence (GPQG/IWGQ) was chosen
based on data regarding the most frequently cleaved sequence by the MMPs that are in most
inflammatory processes28, 30, 31. The Arg-Cys-Arg sequence was chosen to place the single cysteine
residue in an environment that would favor its reactivity. The exact sequences of both CCLP3 and
PCLP3 are shown in Table 2.1 below. Notice the difference in the net charge on the two proteins.
All studies in this thesis are on the CCLP3 construct.
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MW (g/mol)

CCLP3

58675

Theoretical PI

Net Charge at pH 7

4.26

-68

Extinction
Coefficient at 280
nm (M-1cm-1)
32430

Amino acid Sequence
MGSSHHHHHHSSGLVPRGSHMARMADQLTEEQIAEFKEAFSLFDKDGDGTITTKELG
TVMRSLGQNPTEAELQDMINEVDADGNGTIDFPEFLTMMARKMKDTDSEEEIREAFRV
FDKDGNGYISAAELRHVMTNLGEKLTDEEVDEMIREADIDGDGQVNYEEFVQMMTA
KGSGYGGPQGIWGQSGYGGSMADQLTEEQIAEFKEAFSLFDKDGDGTITTKELGTVMR
SLGQNPTEAELQDMINEVDADGNGTIDFPEFLTMMARKMKDTDSEEEIREAFRVFDKD
GNGYISAAELRHVMTNLGEKLTDEEVDEMIREADIDGDGQVNYEEFVQMMTAKGSG
YGGPQGIWGQSGYGGSMADQLTEEQIAEFKEAFSLFDKDGDGTITTKELGTVMRSLGQ
NPTEAELQDMINEVDADGNGTIDFPEFLTMMARKMKDTDSEEEIREAFRVFDKDGNG
YISAAELRHVMTNLGEKLTDEEVDEMIREADIDGDGQVNYEEFVQMMTAKGSGYGGP
QGIWGQGSGYGSRCR

PCLP3

19309

11.62

+22

35540

Amino acid Sequence
MGSSHHHHHHSSGLVPRGSHMASMTGGQQMGRGSKRRWKKNFIAVSAANRFKKISS
SGALELDSTQGPQGIWGQGGRRSGYGGSKRRWKKNFIAVSAANRFKKISSSGALELDS
TQGPQGIWGQGSENSGKRRWKKNFIAVSAANRFKKISSSGALELDSTQGPQGIWGQGS
ENSGRCR

Table 2.1: Relevant Characteristics of CCLP3 and PCLP3
The Molecular Weight (MW) was calculated from the amino acid sequence, while the
isoelectric point (PI), net charge at pH 7, and extinction coefficient were found from
https://web.expasy.org/compute_pi/. Labels: Calmodulin sequence is in blue, His6
sequence is bolded, Collagenase Cleavage site is red underlined, The thrombin cleavage
site is underlined black, the T7 tag is orange, M13 sequence is green, and the cysteines are
red bolded.
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II.

Traut’s Reagent
A. Traut’s Reagent Background
Studies in this thesis were supported by work from earlier students in the Pedigo lab.

Traut’s Reagent is a cyclic thioimidate compound for thiolation or sulfhydryl addition6. The cyclic
iminothiolane structure of Traut’s opens to react with a free amine on proteins modify the protein
with new sulfhydryl groups at the N-terminus and side chains of lysines of the protein. Traut’s
Reagent, which is known by its chemical name as 2-Iminothiolane HCl, was sought out to be a
reliable reagent to allow the reactive primary amines on our protein to introduce new sulfhydryl
groups and increase the number of reaction sites for NSAIDs while maintaining similar
characteristics of the original protein. This reagent allows for spontaneous and efficient methods
to react with primary amines at a pH range of 7-9 because it is very stable with acidic and neutral
buffers that do not contain primary amines. These characteristics allow Traut’s to be used with a
variety of non-amino buffers. After the reaction is complete, it must be desalted using dialysis to
remove small molecules and impurities, like salt, to purify the newly formed thiol addition version
of CCLP3. Because of Traut’s cyclic structure, the new sulfhydryl groups exposed on CCLP3 must
be protected to prevent recyclization or oxidation. Its reversible nature contributes to the short life
span before it reverts to a cyclic structure that is ineffective in attaching NSAIDs later. To prevent
the reversible nature of the protein from cyclically reforming, or from reforming due to changes
in pH not within range, we reacted modified CCLP3 with Ellman’s Reagent, as a stable protector32.
B. Traut’s Chemistry
Traut’s Reagent, also known as 2-iminothiolane, is a reagent used to modify primary
amines such that a sulfhydryl is formed. The beginning reagents are shown in Figure 2.1A, and
the final modified amine in Figure 2.1B. This is particularly useful for creating multiple sulfhydryl
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sites on a protein for later reaction with thiol-reactive groups as attachment sites for drugs. In our
experiment, we tested the success of this experiment with a sulfhydryl quantifying reagent like
Ellman’s Reagent.

Figure 2.1: Reactivity of Traut’s Reagent
(A) (Left) Traut’s Reagent and (Right) the amino acid Lysine. As our protein has 24
lysines, Traut’s Reagent will be immensely useful in creating sulfhydryl groups for further
modification. (B) Lysine after reaction with Traut’s Reagent.
As Figure 2.1 B shows, reacting Traut’s Reagent with the lysine’s  amino group in CCLP3
allows a terminal sulfhydryl group to be formed, much like cysteine. The primary amine breaks
open the 5-membered (four carbon one sulfur) ring, and then it forms an amidine functional group
with the Traut’s Reagent. Traut’s Reagent also performs a similar reaction with the terminal amine
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of the protein. This leads to an expected yield of 26 sulfhydryl groups: 1 terminal amine, 24 lysines,
and 1 cysteine. The actual amount of sulfhydryl groups created will be quantified later once further
reacted with Ellman’s Reagent.
This reaction suffers from the problem that it is reversible. The sulfur can act as a
nucleophile and attack the carbon of the amidine functional group and reverse the reaction. Thus,
we fear the Traut-modified protein is unstable. (see Discussion) Thus, we sought a second means
to modify the protein that afforded control over the reactivity of the thiol group.

C. SATA
SATA, or N-succinimidyl-S-acetylthioacetate, is another chemical that can modify
primary amine groups into terminal sulfhydryl groups. Figure 2.2 shows the reaction between
SATA and the amino acid lysine. SATA combines with the lysine by removing the Nhydroxysuccinimide group from SATA and forming an amide bond. SATA has the benefit of
protecting the modified lysine from sulfur oxidation since the sulfur is protected until needed.
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Figure 2.2: Lysine and SATA reaction

The reaction shown in Figure 2.3 shows the SATA-modified lysine becoming unprotected
through its reaction with hydroxylamine. The hydroxylamine attacks the carbonyl carbon of the
acetyl group protecting the sulfur, thus forming an amide bond with the SATA-modified lysine
and N-hydroxy-acetamide becomes a leaving group. This leaves a sulfhydryl-modified lysine
ready for further modification or quantification, like quantification with Ellman’s Reagent.
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Figure 2.3: SATA-modified Lysine reaction with Hydroxylamine
This second reaction shows the deprotection of the sulfhydryl so that it can be subsequently
reacted with a reactive drug linked to a maleimide group.

D. Ellman’s Reagent
Throughout our experiments, we used Ellman’s Reagent to quantify the efficiency of our
sulfhydryl creating Traut’s Reagent and SATA reactions. Ellman’s Reagent is a good quantifier of
sulfhydryl groups due to its reaction and clear color change in the visible region of the spectrum
in the presence of sulfhydryl groups. The absorbance is measured at 412 nm. Figure 2.4 shows the
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reaction of Ellman’s Reagent and a sulfhydryl-containing compound (in our example cysteine).
The sulfhydryl group attacks the disulfide bond of Ellman’s Reagent, forming a mixed disulfide.
The remaining product is 2-nitro-5-thiobenzoic acid (TNB2-), which is fluorescent at 410 nm. This
allows us to quantify the number of sulfhydryl groups in CCLP3.

Figure 2.4: Ellman’s reaction.
The reaction of Ellman’s Reagent (DTNB2- / 5,5-dithio-bis-(2-nitrobenzoic acid)) and
cysteine to a mixed disulfide and TNB2- (2-nitro-5-thiobenzoate).
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Chapter 3
Materials and Methods

I.

Determining the Purity of Our Lyophilized CCLP3
Because CCLP3 was available as a dry powder, we were concerned about salt

contamination in the lyophilized CCLP3 preparation. To determine the fraction of protein in our
lyophilized CCLP3, and thus to determine the percent amount of CCLP3 that should be used in
calculations, the following experiment was performed. We began by using Beer’s Law to
determine an appropriate concentration of CCLP3 needed to have an absorbance of 1 when read
at 280 nm. By using the extinction coefficient of 32550 cm-1 M-1 33, we determined that the required
protein concentration would be 30.7 μM. Using this, along with a projected total volume of 1 mL
of buffer and the molecular weight of CCLP3 being 58676 g/mol, it was determined that 0.018 g
of CCLP3 was needed in 1 mL of buffer to achieve a 30.7 μM concentration. We then combined
0.018 g of CCLP3 with 1 mL of 10 mM HEPES and 140 mM NaCl buffer, pH 7.4, and read the
absorbance spectrum from 200-350 nm on a Cary 50 Bio UV-Visible Spectrophotometer in a 1
cm quartz cuvette using the SimpleReads program. The specific absorbance at 280 nm and reported
extinction coefficient above were then used to calculate the actual concentration of the prepared
stock. The difference between the projected and prepared stock concentrations provided the
percent purity of the CCLP3 protein preparation in terms of contaminating salts. The results of this
experiment can be seen in Chapter 4.
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II.

SDS-PAGE to Assess Purity and Molecular Weight of CCLP3
To determine the purity and molecular weight of CCLP3 in the protein preparation, we

performed a Tris-Glycine SDS-PAGE analysis of our protein stock of ten lanes with varying
concentrations of CCLP3.
The gel was poured and polymerized in-house and comprised a 17% acrylamide:
bisacrylamide (30:1) gel matrix, run under reducing and denaturing conditions. We created a
running buffer made with 35 mL of 10x Tris-Glycine running buffer solution, 215 mL of water,
and 3.5 mL of 10% SDS mixed in a large, graduated cylinder. We filled the chamber between the
gel and the buffer dam with the running buffer to make sure the seal was watertight. For the sample
dilutions, we used the 10 mM HEPES, 140 mM NaCl, and pH 7.4 buffer to create three dilutions
of the protein stock (1:1; 1:10; and then 1:20). Each of these sample concentrations was diluted
1:1 in reducing, denaturing loading buffer containing bromophenol blue. Following this, we loaded
the lanes in the gel. Lane 1 was created by using 5 μL of EZ-Run MW standard solution (FisherSci)
to establish a calibration for the molecular weight of samples. Lane 2 was empty. Lanes 3-5
contained 2.5, 5, or 10 μL respectively of the 1:1 CCLP3 to buffer dilution. Lanes 6-8 contained
2.5, 5, or 10 μL respectively of 1:10 CCLP3 to buffer dilution. Finally, Lanes 9-10 contained 5 or
10 μL respectively of 1:20 CCLP3 to buffer dilution.
The gel was then run at 200 volts for sixty minutes at room temperature. At the thirtyminute mark, we noticed that the samples were moving down the gel and that the dye front was a
thin blue line, indicating that the stacking process worked well, and the electrophoretic process
was working normally. After the gel was completed, it was placed in the Coomassie blue staining
solution overnight. The following day, the gel was destained in methanol, dilute acetic acid. The
results of this experiment can be seen in Chapter 4.
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III.

Reacting CCLP3 with Traut’s Reagent in an Aerobic Environment
Traut’s reagent is the common name for 2-iminothiolane, a common reagent for modifying

amines to create reactive sulfhydryl groups. This experiment required multiple iterations to
optimize the protocol. These results can be found in Chapter 4.

A. Conversion of Primary Amines to Sulfhydryl Groups with Traut’s Reagent
To be able to increase the number of reactive sulfhydryl groups in CCLP3, we used Traut’s
reagent to be able to convert the primary amine groups of the 24 lysines and the N-terminus of the
protein to sulfhydryl groups. Along with the one cysteine already present in the protein, this would
give us a theoretical yield of 26 sulfhydryl groups.
We began by using 5 mg of lyophilized CCLP3. A solution of CCLP3 was prepared at the
concentration of 10 mg/mL in 0.1 M sodium phosphate, 1 mM EDTA, pH 8.0. Following this,
Traut’s reagent (2-iminothiolane) was prepared in 2 mg/mL concentration by adding 10 mg of
Traut’s to 1 mL buffer solution. The solution was proportioned in a 1:50 mole ratio (CCLP3: 2iminothiolane) by adding 54 μL of Traut’s solution to the 0.5 mL protein solution. Next, for 1
hour, the process was carried out in a shaker. Following this, unreacted Traut’s reagent was
removed by dialysis for 6 hours, with solvent replacement every two hours for a total of three
rotations. At the end of these buffer exchanges, we projected a starting and ending concentration
of 139 μM CCLP3; however, we had a starting concentration of 7 mM Traut’s reagent and an
ending concentration of 878 pM. The protein was then much more concentrated in the diluted
sample with a negligible amount of Traut’s reagent (approximately 0.00000629% of the solution
was Traut’s reagent). We then ran an SDS-PAGE experiment to assess the state of the protein. The
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results of the gel can be seen in Chapter 4. We then used Ellman’s reagent to determine the
sulfhydryl groups in our newly modified protein.

B. Quantification of Sulfhydryl Groups using Ellman’s Reagent
To quantify the number of sulfhydryl groups that were created from the reaction of CCLP3
with Traut’s reagent, Ellman’s reagent was used. Since Ellman’s reagent is very reactive, highly
specific for sulfhydryl groups at neutral pH, and has a high extinction coefficient, it was selected
to quantify the number of sulfhydryl groups. Furthermore, the presence of sulfhydryl groups can
be immediately determined since Ellman’s reagent turns yellow in the presence of sulfhydryl
groups.
We began by making a Reaction Buffer with the concentration of 0.1 M potassium
phosphate, 1 mM EDTA, pH 8.0. Finally, we added water until the total is 500 mL of buffer. We
then made Ellman’s standards with dilute cysteine hydrochloride monohydrate as described in
Table 3.1.

Table 3.1: The Ellman’s Reagent Standards

Standard

Volume Reaction
Buffer

Amount of Cysteine

Final Concentration

A

100 mL

26.34 mg

1.5 mM

B

5 mL

25 mL of A

1.25 mM

C

10 mL

20 mL of A

1.0 mM

D

15 mL

15 mL of A

0.75 mM

E

20 mL

10 mL of A

0.50 mM
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F

25 mL

5 mL of A

0.25 mM

G

5 mL

20 mL F

0.20 mM

H

5 mL

15 mL G

0.15 mM

I

15 mL

10 mL H

0.06 mM

J

15 mL

15 mL I

0.03 mM

K

30 mL

0 mL of A

0.0 mM

Following this, we prepared a set of test tubes, each containing 50 μL of Ellman’s Reagent
Solution (4 mg Ellman’s Reagent in 1 mL of Reaction Buffer) and 2.5 mL of Reaction Buffer. We
then added 250 μL of each standard or unknown to the separate test tubes prepared previously. A
volume of 250 μL of our protein went in the tube labeled L, and 250 μL of standards A-K were
put in their respective tube as well. The test tubes were then mixed and incubated at room
temperature for 15 minutes.
Following this, the absorbance was measured at 412 nm using the 1 cm quartz cuvette on
the Cary 50 Bio UV-Visible Spectrophotometer and SimpleReads program. The values obtained
were then plotted as the standards to generate a standard curve. Using the standard curve and the
absorbance of the unknown, we were able to determine the concentration of sulfhydryl groups in
the post-Traut’s reagent reacted CCLP3. The results of both experiments can be found in Chapter
4.

IV.

Reacting CCLP3 with Traut’s Reagent in an Anaerobic Environment
After reacting the CCLP3 with Traut’s in an aerobic environment, it was determined that a

possible cause of the low cysteine per protein concentration was potential disulfide bonds forming
after reaction with Traut’s reagent. Thus, it was determined that it would be possible to prevent
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the oxidation of sulfhydryl groups into disulfides if the experiment was carried out in an anaerobic
environment.

A. Reacting CCLP3 with Traut’s Reagent under Argon
The experiment was then undertaken under a controlled anaerobic environment that
contained argon instead. We began by using 5 mg of lyophilized CCLP3. This was placed into a
tube that was purged with argon before the CCLP3 was added. Following this, the buffer of 0.1 M
potassium phosphate, 1 mM EDTA, pH 8.0, was placed into the tube via a syringe through the
parafilm. Traut’s reagent (2-iminothiolane) was prepared in 2 mg/mL concentration by adding 10
mg of Traut’s to 1 mL of the buffer solution. The solution was proportioned in a 1:50 mole ratio
(CCLP3: 2-iminothiolane) by adding 54 μL of Traut’s solution to the 0.5 mL protein solution.
Next, for 1 hour, the process was carried out in a shaker while still in the argon environment and
sealed with parafilm. Following this, unreacted Traut’s reagent was removed by dialysis for 6
hours, with a rotation every two hours for a total of three rotations. The entire dialysis procedure
was performed with a continuous stream of argon being pumped into the beaker that was covered
with parafilm, as seen in Figure 3.2.
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Figure 3.2: Photo Dialysis under Argon

As with the previous experiment, following the dialysis, we immediately proceeded with
reacting with Ellman’s Reagent. Each of the tubes was purged with argon before being filled with
the Traut-reacted CCLP3. The reaction was carried out using the same standards in Table 3.1, the
sole difference being that the reaction was carried out under constant sparging with Argon. The
results were then analyzed using the Cary 50 Bio UV-Visible Spectrophotometer. These results
can be seen in Chapter 4.

B. Reacting CCLP3 with SATA under Argon
After reacting CCLP3 with Ellman’s Reagent in an aerobic environment, we realized that
it was likely the oxidation of sulfhydryl groups that was causing Ellman’s quantification to reveal
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fewer sulfhydryl groups than expected. While reacting under argon was a potential solution to this
problem, we thought it would be more simplistic if we used a reagent other than Traut’s that could
potentially inhibit such oxidation. Thus, we sought out SATA or N-succinimidyl Sacetylthioacetate. SATA is special because it protects the sulfhydryl group until it is deprotected
with hydroxylamine for further reaction. This could produce a long-term solution for the storage
of our reacted protein without having to worry about potential oxidation like you would with
Traut’s Reagent.
To prevent any oxidation potential during the reaction, this experiment was also carried
out within an argon environment. We began by using 10 mg of lyophilized CCLP3. A buffer
solution was created containing 0.1 M sodium phosphate buffer, 1mM EDTA, pH 8.0. A solution
of CCLP3 and buffer was created by combining 10 mg of CCLP3 with 1 mL of the prepared buffer.
We then dissolved 16 mg of SATA in 1 mL of DMSO resulting in an approximately 69.2 mM
solution. This achieves a 250:1 molar ratio of SATA to protein (19.25 micromoles SATA: 77
nanomoles protein). Following this, we combined 1 mL of CCLP3 Solution with 556 μL of the
SATA solution. We mixed the contents and incubated the reaction at room temperature for 30
minutes. The mixture was purified by dialysis for 6 hours, with a rotation every two hours for a
total of three rotations and 500 mL of fresh buffer added each rotation (CCLP3 MW: 58.676 kDa,
SATA MW: 231.23)
When it was time for quantification of the created sulfhydryl groups with Ellman’s
Reagent, we prepared the deacetylation solution. We created a deacetylation solution of 0.5 M
Hydroxylamine, 25 mM EDTA, pH 7.4. We combined 1.0 mL of SATA-modified (acetylated)
protein with 100 µL of the Deacetylation Solution. We then mixed the contents and incubate the
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reaction for 2 hours at room temperature. Following this, we purified the mixture by dialysis under
Argon for 2 hours.
As with the previous experiment, following the dialysis, we immediately proceeded with
reacting with Ellman’s Reagent. Each of the tubes was purged with argon before being filled with
the SATA-reacted CCLP3. The reaction was carried out using the same standards in Table 3.1, the
sole difference being that the reaction was carried out under constant sparging with Argon. The
results were then analyzed using the Cary 50 Bio UV-Visible Spectrophotometer. These results
can be seen in Chapter 4.
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Chapter 4
Results

I.

Characterizing the Lyophilized CCLP3 Stock
Figure 4.1 shows a spectrum of CCLP3 stock. The graph depicts the absorbance of our

lyophilized at the wavelengths between 230-350 nm. As our protein contains 12 tyrosine, 3
tryptophan, and 1 cysteine, the anticipated extinction coefficient is 32550 M-1 cm-1 based on the
equation that stays = aW + bY + cC where a, b, and c are 5690, 1280, and 120 M-1 cm-1,
respectively, and W, Y, and C are the number of tryptophan, tyrosine, and cysteine in CCLP333.

Figure 4.1: The Absorbance vs Wavelength of Lyophilized CCLP3
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Using the extinction coefficient and Beer’s Law of A=bc, we calculated the concentration
of CCLP3 to need an absorbance of 1, or 30.7 μM. Using this concentration, a spectrum was run
on a Cary 50 Bio UV-Visible Spectrophotometer. The measured absorbance was found to be 0.87
at 280 nm, therefore the actual concentration of CCLP3 in solution was approximately 25.5 M,
or 87% protein by weight. For all future experiments, we considered these contaminating salts
when calculating the total mass necessary to prepare a particular protein concentration.

II.

Running an SDS-PAGE to Verify the Presence of CCLP3
To assess the approximate fraction of protein that is full-length CCLP3, we performed gel

electrophoresis. Figure 4.2 shows the results of the SDS-PAGE gel of varying dilutions of CCLP3.

Figure 4.2: Reducing SDS-PAGE Gel Used to Verify Presence of CCLP3
Lane 1 contains the MW ladder (116, 66, 45, 35, 24, 18.4. 14.4 kD top to bottom), Lane 2
was skipped, Lanes 3-5 contained increasing amounts of 1:1 CCLP3 to buffer, Lanes 6-8
contained increasing amounts of 1:10 CCLP3 to buffer, and Lanes 9-10 contained
increasing amounts of 1:20 CCLP3 to buffer.
The SDS-PAGE gel showed that CCLP3, with its molecular weight of 58676 g/mol was
present in every sample, and it is approximately halfway between the 66 kD and the 45 kD
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molecular weight ladder markers. Therefore, one can conclude that CCLP3 was present in our
lyophilized sample with an expected molecular weight.

III.

Reacting CCLP3 with Traut’s Reagent in an Aerobic Environment
A. Basic Assessment of Procedure
We used SDS-PAGE to assess the integrity of the protein and the dialysis procedure. Figure

4.3 shows the results of the SDS-PAGE used to check for both CCLP3 after dialysis and the
leakage of CCLP3 through the dialysis tubing during dialysis. The emptiness of lanes 2-7 shows
that at no time did CCLP3 leak into the dialysis buffer. Furthermore, lanes 8-9 show that CCLP3
was present in the post-dialysis solution. Therefore, we expect the dialysis was successful at
removing Traut’s reagent (MW: 137.63 g/mol) since it is small, hydrophilic, and positively
charged, yet the dialysis allowed CCLP3 (MW: 58676 g/mol) to remain in the dialysis tubing.

Figure 4.3: Reducing SDS-PAGE Used to Check for Presence of CCLP3 after Dialysis
Lane 1: MW Ladder (116, 66, 45, 35, 24, 18.4. 14.4 kD top to bottom).
Lanes 2 and 3: 5 and 10 μL respectively of the dialysis buffer were removed after 2
hours.
Lanes 4 and 5: 5 and 10 μL respectively of the dialysis buffer were removed after 4
hours.
Lanes 6 and 7: 5 and 10 μL respectively of the dialysis buffer were removed after 6
hours.
Lanes 8 and 9: 5 and 10 μL respectively of CCLP3 following dialysis after the reaction of
CCLP3 and Traut’s reagent.
Lane 10: Empty
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B. Quantification of Sulfhydryl Groups using Ellman’s Reagent
1. Experiment 1
Ellman’s reagent is used to quantitate the success of the modification of the protein with
Traut’s reagent. Figure 4.4 shows the results of our cysteine calibration curve compared to the
measured absorbance of Traut’s Reagent reacted CCLP3.

Figure 4.4: Ellman’s Calibration curve and Sample- in air.
The Concentration (mM) vs Absorbance of a Cysteine Calibration Curve and our Purified
CCLP3 Sample after reaction with Traut’s Reagent
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To find the number of cysteines per protein, one must do the previous calculations. The
measured absorbance of the CCLP3 was 0.27227. Using Beer’s Law and Ellman’s Reagent’s
extension coefficient of 14140 M-1 cm-1 gives you a concentration of 19.26 M cysteine in the
CCLP3 sample.
Since we used 70.7 nmol of protein in the 2.8 mL solution it was determined that the
concentration of protein was 6.3 M in the whole solution. Therefore, when you divide the
concentration of cysteine by the concentration of protein, one can determine that there are
approximately 3.1 cysteine/protein molecule. This is about 11.7% of the expected 26 cysteines per
protein molecule that should have formed after reaction with Traut’s Reagent. Therefore, it was
hypothesized that Traut’s Reaction was volatile as Ellman’s protocol was done the following day.
To test this, the experiment was repeated the following day, and Ellman’s protocol was done
immediately after the conclusion of Traut’s Reaction.

2. Experiment 2
Figure 4.5 shows the results of our cysteine calibration curve compared to the measured
absorbance of our t’s Reagent reacted CCLP3. The measured absorbance of the CCLP3 was
0.131. Using Beer’s Law and the Ellman’s Reagent’s extension coefficient of 14140 M-1 cm-1
gives you a concentration of 9.26 M cysteine in the CCLP3 sample.
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Figure 4.5: Ellman’s Calibration curve and Sample- in air second trial.
The Concentration (mM) vs Absorbance of a Cysteine Calibration Curve and our Purified
CCLP3 Sample after reaction with Traut’s Reagent
As above, our protein concentration was 6.3 M. Therefore, it was determined that there
are approximately 1.5 cysteine/protein molecule. This is about 5.7% of the expected 26 cysteines
per protein molecule that should have formed after reaction with Traut’s Reagent. Therefore, our
hypothesis about Traut’s reaction being volatile was seemingly confirmed.
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IV.

Reacting CCLP3 in an Anaerobic Environment
A. Reacting CCLP3 with Ellman’s Reagent under Argon
Figure 4.6 shows the results of our cysteine calibration curve compared to the measured

absorbance of Traut’s Reagent reacted CCLP3. The measured absorbance of the CCLP3 was
0.868. Using Beer’s Law and Ellman’s Reagent’s extension coefficient of 14140 M-1 cm-1 gives
you a concentration of 61.39 M cysteine in the CCLP3 sample.

Figure 4.6: Ellman’s Calibration curve and Sample- under Argon.
The Concentration (mM) vs Absorbance of a Cysteine Calibration Curve and our Purified
CCLP3 Sample after reaction with Traut’s Reagent under Argon
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Like the aerobic reactions, our protein concentration was 6.3 M. Therefore, it was
determined that there are approximately 9.74 cysteine/protein molecule, about 37.4% of the
expected 26 cysteines per protein molecule that should have formed after reaction with Traut’s
Reagent. Since the only variable we changed was whether the experiment was done in an aerobic
or anaerobic environment, we determined that it was likely that the aerobic environment was not
suitable for Traut’s reaction and Ellman’s quantification due to the oxidation of the created
sulfhydryl groups.

B. Reacting CCLP3 with SATA under Argon

Figure 4.7: The Concentration (mM) vs Absorbance of a Cysteine Calibration Curve and
our Purified CCLP3 Sample after reaction with SATA under Argon
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Figure 4.7 shows the results of our cysteine calibration curve compared to the measured
absorbance of our SATA reacted CCLP3. The measured absorbance of the CCLP3 was 0.979.
Using Beer’s Law and Ellman’s Reagent’s extension coefficient of 14140 M-1 cm-1 gives you a
concentration of 69.23 M cysteine in the CCLP3 sample.
Contrary to the previous reactions, because we used a differing amount of CCLP3 (10
mg), we determined there were 153 nmol CCLP3. Thus, it was determined the concentration of
CCLP3 in our solution was 13.66 M. Therefore, we calculated that there are approximately 5.1
cysteine/protein molecule, about 19.1% of the expected 26 cysteines per protein molecule that
should have formed after reaction with SATA. Since SATA reactivity is partially determined by
the molar concentration ratio with SATA to the protein to be reacted, this was likely the cause of
our less reactive results. The efficiency of SATA will be discussed more in Chapter 5.
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Chapter 5
Discussion

The main goal of this experiment was to create a process that was suitable for adding
sulfhydryl groups to our CCLP3 protein such that potential drugs could be attached to our protein
for use in a hydrogel. Sulfhydryl groups are rare in proteins as they are only found in one amino
acid, cysteine. Most of the cysteines found in proteins are easily oxidized from the combination of
two cysteines to form the amino acid cystine. Sulfhydryl groups are also reactive to multiple types
of chemistries including reactions with themselves (as mentioned above) and reactions that involve
them being the reducing agent of a reaction due to their easily donatable hydrogen. They
furthermore are important in the creation of protein networks by the creation of sulfhydryl bonds
between multiple cysteine groups. These bonds help establish a protein network between multiple
proteins such as in a protein consisting of multiple units of itself.
We explored the use of two reagents that reacted with free amines such as those on the side
chains of Lysines and the N-terminus of CCLP3, our protein of interest. The different methods
used produced differing results that ranged from feasible for the addition of sulfhydryl groups to
others that are less successful. Here we will discuss the different aspects of the results, while also
expanding on what this could mean for future experiments.
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I.

Reacting CCLP3 with Traut’s Reagent in an Aerobic Environment
The reaction of CCLP3 with Traut’s Reagent carried out in an aerobic environment

produced fewer modification sites than expected. The number of expected sulfhydryl groups after
modification is twenty-six, accounting for the twenty-four lysines, one terminal amine, and one
cysteine already present.

However, using this method, we only achieved the creation of

approximately 3.1 cysteines per protein molecule. We repeated the experiment and received
similar results with 1.5 cysteines per protein molecule. Since there is already one cysteine in
CCLP3, the expected results are much lower than anticipated as there were twenty-five amino
groups that were to be converted to sulfhydryl groups with Traut’s Reagent. Thus, we expected
that there was some other complication causing the error.
Based on the chemistry of both Traut’s Reagent and sulfhydryl groups in general, we
hypothesized that there was potential oxidation of the sulfhydryl groups into a disulfide linkage.
The formation of a disulfide would deactivate the reagent, and the protein wouldn’t be modified.
This would cause a lower-than-expected result following the quantification of sulfhydryl groups
with Ellman’s Reagent. Therefore, we determined that the experiment should be repeated in an
anaerobic environment.

II.

Reacting CCLP3 with Traut’s Reagent in an Anaerobic Environment
The reaction of CCLP3 with Traut’s Reagent in an anaerobic environment produced better

results than the aerobic reaction, as expected. With approximately 9.74 sulfhydryl/protein, there
was more than a 3x improvement compared to the aerobic reactions. Thus, we determined that
there was some validity to our hypothesis that there was oxidation of sulfhydryl groups in the
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aerobic reactions. Therefore, we recommend that for future experiments all reactions be carried
out in an anaerobic environment, particularly under an inert gas atmosphere like argon.
Even though the results were greater than reactions in aerobic conditions, the results
provided only about 37.4% of the expected 26 reaction sites/protein. We believe this may have
something to do with the fact the reaction took place with only a 1:50 mole ratio of CCLP: 2iminiothiolane (Traut’s Reagent). This is only a 1:2 mole ratio of Traut’s Reagent to reaction sites.
By potentially increasing the ratio of Traut’s Reagent, we predict there could be greater reactivity.
Another issue is the potential oxidation of sulfhydryl groups, as no matter, the environment used
there is always the potential for the possible introduction of oxygen to the environment. One of
the possible ways to mitigate this issue is the addition of a reducing agent, like dithiothreitol (DTT).
This could be added at the beginning of the process and removed during the dialysis step.
Furthermore, a reducing agent like tris(2-carboxyethyl)phosphine (TCEP) could be used the
following dialysis as it would not interfere with the quantification of sulfhydryl groups by Ellman’s
Reagent as it contains no sulfhydryl groups itself.

III.

Reacting CCLP3 with SATA under Argon
Our third and final attempt at adding sulfhydryl groups used SATA rather than Traut’s

Reagent. This attempt was also undertaken in an anaerobic environment, even though SATA sulfur
is protected in the form of a thioester, and therefore oxidation was not expected to occur until it
was deprotected with hydroxylamine later in the experiment. Our results produced an
approximately 5.1 sulfhydryl/protein molecule. Although this was lower than Traut’s Reagent
modification in an anaerobic environment, it was higher than Traut’s Reagent modification in an
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aerobic environment, making it our second-best option for sulfhydryl creation in terms of raw
results.
Furthermore, the efficiency of SATA is based upon the molar ratio to the protein to be
modified30. We used a 250:1 molar ratio of SATA: protein, however, a higher molar ratio would
be more efficient. When reacted with bovine serum albumin (BSA), a 250:1 mole ratio of SATA:
BSA had a 54.41% efficiency of converting primary amines to sulfhydryl groups6. Sulfhydryl
incorporation increased with greater amounts of SATA, but with decreasing efficiency6. Compared
to our 19.1% efficiency of turning CCLP3 primary amines into sulfhydryl groups, we may have
also potentially created oxidized sulfhydryl groups during the Ellman’s Reagent quantification
portion of the experiment. Thus, by both increasing the molar ratio and adding a reducing agent
after the deprotection of the sulfhydryl group with hydroxylamine, a future experiment could
potentially see greater results in sulfhydryl conversion.

IV.

Future Studies: Applying NSAIDs to the Hydrogel
In continuation of our work to apply to future experiments and to advance our knowledge

on the usage of hydrogels as an in-situ source of drug delivery, our results can be applied to allow
linkages of our sulfhydryl groups to NSAIDs. With the assistance of Dr. Watkins’s lab and
specifically Mr. Blaine Derbigny, experiments are advancing by applying a standard NHydroxysuccinimide (NHS) ester protocol. NHS is an organic compound, composed of ester
terminal groups, and used for amine coupling reactions in bioconjugation, or in other words, to
create covalent bonds, via amide linkages, between amine-containing molecules to exteriors of
other molecules34. Finding a protocol that allows for a high percentage yield of linkages to further
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explore its ability to function and maintain properties in vivo is a top priority for advancing this
work.
Throughout these experiments, our team employed many strategies to target sulfhydryl
groups specifically disulfide formation, which is reversible, but relevant to the oxidizing
conditions in the extracellular space. Our polymers are engineered to have CCLP3. CCLP3 thiols
are involved in the chemical bond to form the higher-order structure of polymers discussed and
can be unavailable for modification with a drug. For this reason, we applied Traut’s reagent in an
aerobic environment and Traut’s Reagent and SATA in an anaerobic atmosphere to initiate the
presence of thiols for the development of biomaterials35,

36

, which essentially converts the

polypeptide into a poly thiol template through reaction with amines. Under basic conditions, a
nonreactive cyclic compound forms,

37, 38,

and thus, the timing and order of completion were an

utmost priority in this lab.
In Figure 5.1, we outlined the continuing process that future labs will apply to their
protocols. From the scheme below, they will prepare a stable and modified drug through a reaction
N-(2-hydroxyethyl) maleimide, a linking group that creates an ester to the carboxylate of the drug,
that is tethered to maleimide through a 2-carbon chain. This reaction will be carried out in an
aprotic solvent to ensure that the maleimide is not deactivated by water. In addition, they can
easily lengthen the carbon chain to reduce restrictive or steric effects of the protein backbone on
drug release. Separately, using our findings, CCLP3 will be treated with Traut’s reagent which
will react with amines to create up to 25 -SH sites. The Naproxen-ester-S-Maleimide will then be
added to create f-CCLP3. Formation of the Hydrogel: f-CCLP3 would then be added to PCLP3.
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Figure 5.1: Strategy for the modification of thiols
Modification of Polymer Scheme: Right: React CCLP3 with Traut’s reagent to create
CCLP3-poly-SH. Left: Activate naproxen by forming an ester linkage to the carboxylate
using 6-MNH (6-Maleimidohexanoic acid N-hydroxy succinimide ester), which links the
naproxen to maleimide. Mixing Products 2 and 4 will yield functionalized CCLP3

V. Conclusion
After exploring a variety of ways to construct CCLP3 to add thiols, we found that Traut’s
Reagent in an anaerobic environment proved the most beneficial in our goal of creating a reactive
CCLP3 that could be tested once Naproxen is modified. The importance of our work is clearly
shown with the prevalence of overprescribing NSAIDs in the world. Through research, we have
acknowledged the benefits that hydrogels can provide to a system that continuously approaches
complications with the standard way of ingesting the medication. Further studies can be conducted
to increase the overall modification capabilities of each polymer as well as hydrogels. Drug
compounds using the maleimide linkage can be constructed, creating a drug-modified polymer.
Our study has prepared the next step in our overall goal, which is to create hydrogel that can serve
as a drug depot for specified regions in the body.
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